Sara Delfanti

6PUBLICATIONS
33CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Predictive and prognostic markersPathology (excl. oral pathology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 27, 2026
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.

|Dec 12, 2025
Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases.

Luigi Cerbone, Benedetta Del Rio, Sara Delfanti

|Jun 17, 2025
Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after checkpoint inhibitor treatment: a case report.

Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati

|Dec 23, 2023
Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack.

Luigi Cerbone, Sara Orecchia, Pietro Bertino

|May 28, 2022
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study.

Laura Mannarino, Lara Paracchini, Federica Pezzuto

|Dec 06, 2019
Comparison of pathology sampling protocols for pancreatoduodenectomy specimens.

Federica Grillo, Jacopo Ferro, Alessandro Vanoli

Pageof 1

Frequent Collaborators

1 joint publications

Federica Grillo

1 joint publications

Jacopo Ferro

1 joint publications

Alessandro Vanoli

1 joint publications

Francesca Pitto